Recent developments include a merger agreement with Chiesi Farmaceutici S.p.A., positive interim Phase 3 data for EKTERLY, and recognition of EKTERLY in pediatric HAE treatment guidelines. The company reported preliminary revenue figures and maintains a strong liquidity position. Executive appointments and capital raising activities have also been announced.

• KalVista Pharmaceuticals entered into a merger agreement with Chiesi Farmaceutici S.p.A. on April 29, 2026, including a tender offer to acquire all outstanding shares at $27.00 per share in cash [N1].
• The company announced positive interim Phase 3 data from the EKTERLY study, supporting clinical progress [N3].
• EKTERLY was recommended as a first-line treatment in new pediatric hereditary angioedema guidelines, enhancing its clinical positioning [N7].
• Preliminary global net revenue was approximately $35 million for the quarter and $49 million for the eight-month transition period ended December 31, 2025 [S1].
• KalVista maintains a strong liquidity position with $229.3 million in cash and equivalents and a current ratio of 5.58 as of December 31, 2025 [S1].
• Bilal Arif was appointed Chief Operating Officer effective October 6, 2025, with a comprehensive employment agreement [S1].

KalVista has demonstrated clinical progress with positive interim Phase 3 data for EKTERLY and regulatory endorsements, supporting its potential to expand market adoption in hereditary angioedema treatment. The company's strong liquidity and recent capital raise provide resources for commercialization and strategic initiatives. The merger agreement with Chiesi Farmaceutici S.p.A. may offer operational synergies and expanded market reach. Continued successful clinical trial outcomes and regulatory approvals could enhance the company's commercial prospects.

KalVista faces significant risks including the uncertainty of completing the merger transaction, potential delays or failures in regulatory approvals, and challenges in commercializing EKTERLY amid competitive pressures. The company reported a substantial net loss in 2025, reflecting ongoing investment and operational costs. Integration risks post-merger and broader industry and economic conditions may impact business performance. Clinical trial outcomes remain uncertain, and failure to achieve key milestones could adversely affect the company's prospects.

KalVista's moat is primarily based on its specialized pharmaceutical development in hereditary angioedema treatments, with EKTERLY as a differentiated product supported by positive Phase 3 clinical data and inclusion in pediatric treatment guidelines. The company's ongoing clinical trials and regulatory progress contribute to its competitive positioning. However, the pharmaceutical industry is highly competitive and subject to regulatory risks, which may challenge sustained differentiation.

• Merger Completion Risk: The merger with Chiesi Farmaceutici S.p.A. is subject to conditions and regulatory approvals, with the possibility that the acquisition may not close or may be delayed.
• Regulatory Approval Uncertainty: The timing and outcome of regulatory approvals for EKTERLY and other product candidates remain uncertain and could impact commercialization efforts.
• Commercialization and Market Adoption: The success of EKTERLY's commercialization depends on market acceptance, competitive products, pricing pressures, and the company's ability to execute its sales and marketing strategies.
• Financial Performance and Losses: KalVista reported a net loss of $109.5 million for 2025, indicating ongoing investment needs and potential financial risks if revenue growth does not materialize.
• Integration and Operational Risks: Post-merger integration challenges may affect business operations and the realization of anticipated benefits from the transaction.

• KalVista Pharmaceuticals, Inc. is a Delaware corporation headquartered in Framingham, Massachusetts, USA.
• The company is publicly traded on NASDAQ under the ticker KALV.
• KalVista focuses on pharmaceutical development, with EKTERLY as a key product, recommended as a first-line treatment in new pediatric hereditary angioedema (HAE) guidelines.
• The company announced positive interim Phase 3 data from the EKTERLY study, indicating clinical progress.
• KalVista reported preliminary global net revenue of approximately $35 million for the quarter ended December 31, 2025, and $49 million for the eight-month transition period ending the same date.
• For the fiscal year ended December 31, 2025, KalVista reported revenue of $13.7 million and a net loss of $109.5 million, with basic and diluted EPS of -2.03 USD per share.
• As of December 31, 2025, the company held $229.3 million in cash and cash equivalents, with current assets of $320.1 million and current liabilities of $57.4 million, resulting in a strong current ratio of 5.58 and a cash ratio of 4.0.
• KalVista completed a $143.75 million private placement of 3.250% Convertible Senior Notes due 2031 in September 2025, with net proceeds intended for working capital, commercialization of EKTERLY, and potential acquisitions.
• On April 29, 2026, KalVista entered into a merger agreement with Chiesi Farmaceutici S.p.A., including a tender offer to acquire all outstanding shares at $27.00 per share in cash.
• The merger agreement includes customary representations, warranties, covenants, and non-solicitation restrictions, with a termination fee of $66.4 million payable under certain conditions.
• The company appointed Bilal Arif as Chief Operating Officer effective October 6, 2025, with a detailed employment agreement including salary, bonus, stock options, and severance provisions.
• KalVista's business involves regulatory approvals, commercialization efforts, clinical trials (including KONFIDENT-S and KONFIDENT-KID), and international expansion plans.
• The company faces risks related to timing and completion of the merger, regulatory approvals, competitive products and pricing, integration challenges post-merger, and general industry and economic conditions.